SYD-101 - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Saipem wins $121m offshore drilling contracts in Cyprus and Ghana as fleet utilisation strengthens

Conrad Bengaluru pool deaths: Police probe lighting fault as two foreigners die

Waaree Renewable Technologies (NSE: WAAREERTL) adds battery storage and solar contracts, but will margins recover?

KMD Brands enters exclusive Bluestar Alliance takeover talks after NZ$414m loss

Sydnexis receives European Commission approval for SYD-101, the first pharmaceutical treatment to slow pediatric myopia progression; Santen to launch the drug as Ryjunea across Europe.

Read More

Pharma Industry News

Myopia drug breakthrough: Sydnexis’ SYD-101 approved in Europe, Ryjunea launch next

Sydnexis, Inc., a privately held U.S. biopharmaceutical company, secured a critical regulatory victory on June 5, 2025, with…

byPallavi Madhiraju

June 6, 2025

web analytics